Join
Live feed
·
PRReleasevia Quantisnow
Stoke Therapeutics Inc. logo
Biogen Inc. logo

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
STOK· Stoke Therapeutics Inc.BIIB· Biogen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.), BIIB (Biogen Inc.) and more on Quantisnow.

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome | Quantisnow